Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB-119 Phase 2 Dose-Finding Study in T2DM
NCT03604419Phase 2Completed
- Sponsor
- PegBio
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of visepegenatide in type 2 diabetes mellitus (T2DM), sponsored by PegBio. Started Jun 2018; status: completed.
02
Drugs
visepegenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03604419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604419.